Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 12/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91106 | 0.90 | HRH3 (0.51) | HPGDSPRKAA2HRH3SCN9A | |
| SCHEMBL16194601 | 0.90 | PRKAA2 (0.48) | HPGDSPRKAA2SLC6A5HRH3DRD4 | |
| SCHEMBL61833 | 0.89 | HDAC4 (0.49) | HPGDSPRKAA2SLC6A5 | |
| SCHEMBL63038 | 0.89 | HPGDS (0.51) | HPGDSPRKAA2HRH3SCN9A | |
| SCHEMBL62194 | 0.88 | DRD4 (0.56) | PRKAA2SLC6A5DRD4 | |
| SCHEMBL61881 | 0.86 | SLC6A5 (0.58) | PRKAA2SLC6A5DRD4 | |
| SCHEMBL91109 | 0.86 | DRD4 (0.52) | PRKAA2SLC6A5DRD4 | |
| SCHEMBL3664140 | 0.85 | HPGDS (0.42) | HPGDSPRKAA2SLC6A5HRH3DRD4 | |
| SCHEMBL61677 | 0.83 | PRKAA2 (0.57) | PRKAA2SLC6A5DRD4 | |
| SCHEMBL5020462 | 0.81 | GPR119 (0.50) | HPGDSPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HPGDS 3138/4885PRKAA2 3/4885SLC6A5 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.